NCT01876953 2022-03-31Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid LeukemiaCity of Hope Medical CenterPhase 1/2 Terminated20 enrolled 9 charts
NCT02440568 2021-07-06AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML PatientsUniversity of Illinois at ChicagoPhase 1/2 Terminated22 enrolled 17 charts
NCT01607645 2017-03-31Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDSFred Hutchinson Cancer CenterPhase 2 Terminated7 enrolled 17 charts
NCT00528450 2016-01-29Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic LeukemiaMemorial Sloan Kettering Cancer CenterPhase 2 Terminated1 enrolled 4 charts